cancel
Showing results for 
Search instead for 
Did you mean: 

A new treatment paradigm for men with metastatic castration-resistant prostate cancer

Chris_McNamara
Community Manager
Community Manager
0 0 735

New research has found significant benefits in using olaparib to treat men who have metastatic castration-resistant prostate cancer and BRCA1, BRCA2 or ATM gene mutations.

The treatment is being considered for listing on the Pharmaceutical Benefit Scheme, with consumer comments open from this Thursday December 24 until February 11 next year.

We’ll be advocating to have the treatment listed on the PBS – collecting your comments for submission. Email enquiries@pcfa.org.au for more information and stay posted here.

PROFOUND: OVERALL SURVIVAL DATA WITH OLAPARIB HERALD PRACTICE-CHANGING TREATMENT OF METASTATIC PROSTATE CANCER

A new treatment paradigm for men with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1, BRCA2 or ATM mutations

Date:21 Sep 2020

Source: European Society for Medical Oncology

Excitement over the positive progression-free survival (PFS) data reported last year in the PROfound trial continues, with final overall survival (OS) data presented today at ESMO Virtual Congress 2020 (Abstract 610O) showing significant benefits with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in men with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1BRCA2 or ATM mutations.

PROfound is a prospective, multicentre, randomised, open-label, phase III study evaluating the efficacy and safety of olaparib (300 mg twice daily) versus control (physician’s choice of enzalutamide [160 mg/day] or abiraterone [1000 mg/day]) in 387 patients with mCRPC who had progressed on a new hormonal agent and had a tumour mutation in one of 15 genes that have a role in the homologous recombination repair (HRR) pathway. OS was analysed as a prespecified key secondary endpoint in Cohort A, which comprised patients with alterations in BRCA1BRCA2 or ATM, and the overall population.

At the March 2020 data cut-off, median OS was significantly longer with olaparib than control treatment in Cohort A (19.1 months versus 14.7 months; hazard ratio [HR] 0.69; 95% CI, 0.50–0.97; p=0.0175) with a trend towards improvement in the overall population (17.3 months versus 14.0 months; HR 0.79; 95% CI, 0.61–1.03; nominal p=0.0515). This is despite approximately two-thirds of patients in the control arm crossing over to olaparib following radiographic disease progression. The long-term safety of olaparib was as expected from previous studies of olaparib.

These final OS data from the PROfound trial, alongside the positive PFS data, are very likely to alter the treatment paradigm for patients with mCRPC who can be selected based on their BRCA1BRCA2 or ATM status. It is anticipated that the recent US FDA approval granted to olaparib for the treatment of patients with HRR gene-mutated mCRPC who have progressed following treatment with enzalutamide or abiraterone will be followed by EMA approval in the near future.

https://www.esmo.org/meetings/past-meetings/esmo-virtual-congress-2020/daily-reporter/daily-reporter...

House Rules

To help keep this community a welcoming, supportive and caring place we have put together a small list of dos and don'ts for you to think about when posting on our forum, research blog or video gallery.

For further information please see our terms and conditions, and to contact the Online Community team please email onlinecommunity@pcfa.org.au or call 1800 22 00 99.

Adhere to PCFA’s five core values of Integrity, Optimism, Compassion, Respect and Commitment.

Our online forum is for you to share experiences with others and does not contain specific medical, counselling or legal advice.  If you require professional advice specific to your individual circumstances we encourage you to see a medical professional, legal professional or counsellor.

No commercial or promotional activity. While members may share information about resources they have found helpful, the PCFA Online Community forum should not be used for the promotion of goods and services. This includes commercial entities passing themselves off as individuals and people who frequently post links to external health professionals or other services.

Be kind to each other - many people using the community are going through a difficult time. A few kind words can go a long way. Please welcome new posters – it can be very nerve-wracking to post on the forum for the first time.

If you or someone you know is suffering from mental health issues, such as depression or anxiety, we encourage you to seek assistance and contact Beyond Blue Tel:1300 224 636 or Lifeline Tel:13 11 14

Speak your mind freely, but please be sensitive to the feelings and experiences of others - you might not always agree, but you can agree to disagree in a peaceful manner.

Don't use offensive language -if a user is found to be using offensive language during their conversations the moderators reserve the right to edit the thread, without warning.

Don't use all capital letters in your posts - it's considered ‘shouting' online and it makes posts difficult to read.

Give each other the benefit of the doubt - please remember that it is all too easy for the tone and meaning of posts to be misinterpreted. Think carefully before replying to a discussion. it It is important to remember that things written rather than said can feel much stronger, so please bear this in mind when reading other people's messages.

Please respect the moderators - their job is to keep the forum safe and constructive so that everybody gets to have his or her fair say.

Stay on topic - try to focus on the original topic. In particular, don't change subject in the middle of an existing thread - just start a new thread.

Read what's already on the forum before posting - you may be repeating what others have already said or asked.

We want PCFA's Online Community to be a secure and helpful environment for all of the community. So please remember that by using PCFA's Online Community you are agreeing to follow our terms and conditions.